JP2014527061A - Ｃ型肝炎の組合せ治療 - Google Patents

Ｃ型肝炎の組合せ治療 Download PDF

Info

Publication number
JP2014527061A
JP2014527061A JP2014527322A JP2014527322A JP2014527061A JP 2014527061 A JP2014527061 A JP 2014527061A JP 2014527322 A JP2014527322 A JP 2014527322A JP 2014527322 A JP2014527322 A JP 2014527322A JP 2014527061 A JP2014527061 A JP 2014527061A
Authority
JP
Japan
Prior art keywords
methyl
inhibitor
hcv
imidazol
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527061A5 (enExample
Inventor
ウォーカー，ジル
フォイテンライトナー，クリスティアン
Original Assignee
グラクソスミスクライン エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン エルエルシー filed Critical グラクソスミスクライン エルエルシー
Publication of JP2014527061A publication Critical patent/JP2014527061A/ja
Publication of JP2014527061A5 publication Critical patent/JP2014527061A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014527322A 2011-08-24 2012-08-24 Ｃ型肝炎の組合せ治療 Pending JP2014527061A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161526798P 2011-08-24 2011-08-24
US61/526,798 2011-08-24
US201161529358P 2011-08-31 2011-08-31
US61/529,358 2011-08-31
US201261617813P 2012-03-30 2012-03-30
US61/617,813 2012-03-30
PCT/US2012/052216 WO2013028953A1 (en) 2011-08-24 2012-08-24 Combination treatments for hepatitis c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017083252A Division JP2017165746A (ja) 2011-08-24 2017-04-20 Ｃ型肝炎の組合せ治療

Publications (2)

Publication Number Publication Date
JP2014527061A true JP2014527061A (ja) 2014-10-09
JP2014527061A5 JP2014527061A5 (enExample) 2015-10-08

Family

ID=47746891

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014527322A Pending JP2014527061A (ja) 2011-08-24 2012-08-24 Ｃ型肝炎の組合せ治療
JP2017083252A Pending JP2017165746A (ja) 2011-08-24 2017-04-20 Ｃ型肝炎の組合せ治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017083252A Pending JP2017165746A (ja) 2011-08-24 2017-04-20 Ｃ型肝炎の組合せ治療

Country Status (18)

Country Link
US (1) US20140234253A1 (enExample)
EP (1) EP2747569A4 (enExample)
JP (2) JP2014527061A (enExample)
KR (1) KR20140065427A (enExample)
CN (1) CN103917095A (enExample)
AU (1) AU2012298750A1 (enExample)
BR (1) BR112014004182A2 (enExample)
CA (1) CA2845321A1 (enExample)
CL (1) CL2014000428A1 (enExample)
CO (1) CO6890100A2 (enExample)
CR (1) CR20140086A (enExample)
EA (1) EA201490254A1 (enExample)
HK (1) HK1198869A1 (enExample)
IL (1) IL230844A0 (enExample)
MX (1) MX2014002171A (enExample)
PH (1) PH12014500386A1 (enExample)
SG (1) SG2014010490A (enExample)
WO (1) WO2013028953A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120993A1 (es) * 2009-09-04 2012-08-22 Janssen Pharmaceuticals Inc Derivados bifenilicos como antivirales
KR101975233B1 (ko) 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105705511A (zh) 2013-04-12 2016-06-22 艾其林医药公司 用于治疗hcv的氘化核苷前药
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3019196B1 (en) * 2013-07-09 2018-06-06 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
CA2935089C (en) * 2013-12-31 2018-11-27 Nanjing Sanhome Pharmaceutical Co., Ltd. 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof
CN106279121B (zh) * 2014-01-21 2019-05-24 杭州普晒医药科技有限公司 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
SG11201703645XA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Long acting pharmaceutical compositions for hepatitis c
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110693887B (zh) * 2019-05-17 2022-06-17 歌礼药业（浙江）有限公司 包含索磷布韦和拉维达韦的片剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500413A (ja) * 2006-08-11 2010-01-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
WO2011028596A1 (en) * 2009-09-04 2011-03-10 Glaxosmithkline Llc Chemical compounds
WO2011046811A1 (en) * 2009-10-12 2011-04-21 Bristol-Myers Squibb Company Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
WO2011075439A1 (en) * 2009-12-16 2011-06-23 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2435799T3 (es) * 2008-10-09 2013-12-23 Anadys Pharmaceuticals, Inc. Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales
WO2010062821A1 (en) * 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
MX2011007195A (es) * 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
CA2784748A1 (en) * 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500413A (ja) * 2006-08-11 2010-01-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
WO2011028596A1 (en) * 2009-09-04 2011-03-10 Glaxosmithkline Llc Chemical compounds
WO2011046811A1 (en) * 2009-10-12 2011-04-21 Bristol-Myers Squibb Company Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
WO2011075439A1 (en) * 2009-12-16 2011-06-23 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Also Published As

Publication number Publication date
BR112014004182A2 (pt) 2017-03-14
IL230844A0 (en) 2014-03-31
HK1198869A1 (en) 2015-06-19
EA201490254A1 (ru) 2014-07-30
KR20140065427A (ko) 2014-05-29
EP2747569A1 (en) 2014-07-02
CN103917095A (zh) 2014-07-09
AU2012298750A1 (en) 2014-03-13
CR20140086A (es) 2014-05-02
CO6890100A2 (es) 2014-03-10
WO2013028953A1 (en) 2013-02-28
SG2014010490A (en) 2014-04-28
MX2014002171A (es) 2014-04-25
JP2017165746A (ja) 2017-09-21
CL2014000428A1 (es) 2014-08-01
US20140234253A1 (en) 2014-08-21
PH12014500386A1 (en) 2019-10-07
CA2845321A1 (en) 2013-02-28
EP2747569A4 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
JP2017165746A (ja) Ｃ型肝炎の組合せ治療
AU2011349844B2 (en) Combinations for treating HCV
ES2659216T5 (es) Métodos para el tratamiento del VHC
EP2907816B1 (en) Condensed imidazolylimidazoles as antiviral compounds
AU2011349844A1 (en) Combinations for treating HCV
US20110306541A1 (en) Methods for treating hcv
HK1245262A1 (en) 9-(1h-imidazol-5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazole derivatives and their use as inhibitors of hcv ns5a
EP2734515B1 (en) Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
EP3239153A1 (en) 9-(1h-imidazol-5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazole derivatives and their use as inhibitors of hcv ns5a
WO2013025975A1 (en) Combination treatments for hepatitis c
NZ720391B2 (en) Methods for treating HCV
HK1194692A (en) Methods for treating hcv
HK1194692B (en) Methods for treating hcv
HK1198387B (en) Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161220